Business Standard

Sun Pharma gains 5% as Sebi finds no merit in allegation of fraud

HDFC Securities has 'buy' rating on Sun Pharma with a 12-month target price of Rs 545 as the brokerage expects a recovery in the profitability (24 per cent margin) by FY21E.

Sun Pharma Founder and Managing Director Dilip Shanghvi said the company would grow its speciality drug pipeline globally and expand manufacturing facilities
Premium

Sun Pharma Founder and Managing Director Dilip Shanghvi said the company would grow its speciality drug pipeline globally and expand manufacturing facilities

SI Reporter Mumbai
Shares of Sun Pharmaceutical Industries rallied 5 per cent to Rs 432 apiece in the early morning trade on the BSE on Thursday on reports that the market regulator Securities and Exchange Board of India (Sebi) has found no merit in the allegations of fraud against the company.

At 10:16 am, Sun Pharma was trading 3 per cent higher at Rs 425, and was the top gainer among the S&P BSE Sensex pack. In comparison, the benchmark index was down 0.54 per cent or 200 points at 37,251. The counter witnessed huge trading volumes with a combined 7.2 million

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Aug 29 2019 | 10:41 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com